OncoMatch/Clinical Trials/NCT04322578
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
Is NCT04322578 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Crizotinib and Pemetrexed for non-small cell lung cancer.
Treatment: Crizotinib · Pemetrexed — This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MET exon 14 skipping
MET exon 14 skippign confirmed by an accredited local laboratory
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: EGFR antibody
Treatment with molecules such as EGFR, VEGFR antibodies within 4 weeks prior to the first dose of study drug
Cannot have received: VEGFR antibody
Treatment with molecules such as EGFR, VEGFR antibodies within 4 weeks prior to the first dose of study drug
Cannot have received: radiation therapy
Exception: Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose
Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity
Lab requirements
Blood counts
Adequate bone marrow hematopoiesis
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate bone marrow hematopoiesis and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify